Cocoa Polyphenols for Eosinophilic Esophagitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eosinophilic esophagitis primarily focus on dietary modification to avoid allergens, lacking a composition that actively prevents or treats the condition effectively.
Innovation Solution
A composition comprising cocoa extracts with specific procyanidins, such as procyanidin B1, B2, and their multimers, is used to prevent or treat eosinophilic esophagitis, administered orally or topically to directly address the inflammatory response in the esophagus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary modification by excluding potential food allergens is used, then the allergic response can be reduced, but the treatment lacks active prevention or therapy capability
Solution Approach 1:
The patent introduces cocoa polyphenols as an intermediary substance that mediates the treatment of eosinophilic esophagitis. These polyphenols act as active therapeutic agents that can reduce eosinophil infiltration and inflammation in the esophagus, moving beyond passive dietary avoidance to active biochemical intervention. The polyphenols serve as a bridge between dietary modification and pharmacological treatment.
Solution Approach 2:
The patent changes the chemical parameters of the dietary composition by incorporating specific cocoa polyphenols (procyanidin B1, procyanidin B2, and their multimers) at defined concentrations. This transforms the dietary approach from simple allergen exclusion to a chemically active treatment regime, where specific phytochemical compounds modify the inflammatory response parameters in the esophagus.
2Object-affected harmful factors
If complete nutrition lacking any potential allergens is provided, then allergic inflammatory conditions can be prevented, but the nutritional composition lacks therapeutic active ingredients
Solution Approach 1:
The patent creates a composite nutritional composition that combines allergen-free base nutrients with therapeutic cocoa polyphenol compounds. This composite approach integrates the protective function of allergen exclusion with the therapeutic function of bioactive polyphenols, resulting in a multi-functional nutritional product that both prevents and treats eosinophilic esophagitis.
Solution Approach 2:
Cocoa polyphenols are introduced as intermediary therapeutic agents within the nutritional composition. These compounds mediate the transition from passive nutritional support to active disease modification by reducing eosinophil infiltration and inflammatory signaling in the esophagus, while the nutritional matrix provides the necessary substrate for overall health maintenance.
3Reliability
If conventional medical therapy with corticosteroids is used, then symptoms can be mitigated, but the treatment lacks natural compound-based approaches
Solution Approach 1:
The patent employs natural cocoa polyphenols as transient, renewable therapeutic agents that can be administered through dietary means. Unlike synthetic corticosteroids that require complex pharmaceutical manufacturing and carry long-term side effect risks, the polyphenol-based treatment uses naturally occurring compounds that can be replenished through regular dietary intake, reducing accumulation and chronic toxicity concerns.
Solution Approach 2:
The patent converts the generally beneficial but potentially harmful cocoa polyphenols into a targeted therapeutic agent for eosinophilic esophagitis. By utilizing the natural anti-inflammatory properties of these compounds at specific dosages, the treatment harnesses their beneficial effects while avoiding the severe side effects associated with conventional corticosteroid therapy, particularly in pediatric populations.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to the use of cocoa polyphenols, in particular, procyanidin(s) in the treatment or prevention of eosinophilic esophagitis.